

**Table S1.** Criteria used for primary failure by the studies (included in Table 1) which reported their results stratified by type of failure (primary vs. secondary).

Author	Criteria for primary failure
Casanova [21]	It was considered that the patient had a primary failure if she/he did not achieve remission after having received the induction doses of the anti-TNF (non-responders and partial responders)
Chaparro [22]	For luminal disease, response to adalimumab and infliximab was evaluated using the Harvey-Bradshaw index (HBI) four weeks after the first dose. Partial response was defined as a decrease in the HBI of more than 3 points. Remission was defined as a HBI below or equal to 4 without steroids. In perianal Crohn's disease, complete response was defined as closure of all fistulas and partial response as a 50% or more reduction in the number of draining fistulas.
Cordero Ruiz [24]	No specific definition was provided (just stated "lack of initial response to infliximab")
Cozijnsen [25]	No specific definition was provided (just stated "non-response to infliximab")
Favale [26]	Primary failure was defined as the lack of clinical response based on physician's global assessment (PGA) within 10 weeks from the first induction dose.
Fumery [27]	Primary failure was defined as the absence of clinical remission or clinical response at 6 months after adalimumab initiation
Garcia-Bosch [28]	No specific definition was provided (just stated "primary non-responders to infliximab")
Lichtiger [31]	Primary non-responders to infliximab were defined as patients who never responded to their initial exposure to infliximab
Lofberg [32]	Classification of study subjects as primary non-responders to infliximab was determined by the investigator
Seiderer [35]	No specific definition was provided (just stated "infliximab-refractory")
Sprakes [36]	Primary non-response was defined as individuals who did not respond to the standard three dose induction with infliximab
Viola [39]	No specific definition was provided (just stated "patients unresponsive to adalimumab or golimumab who were switched to infliximab")